Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sembragiline SCHEMBL3365609 | 1.00 | MAOB (1.00) | MAOBMAOATP53LMNAPOLB | |
| Sembragiline SCHEMBL2440939 | 1.00 | MAOB (1.00) | MAOBMAOATP53LMNAPOLB | |
| Sembragiline SCHEMBL29361249 | 1.00 | MAOB (1.00) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3368619 | 0.91 | MAOA (0.84) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3368627 | 0.91 | MAOA (0.84) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3367653 | 0.91 | MAOB (0.84) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3367651 | 0.91 | MAOB (0.84) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3367888 | 0.90 | MAOB (0.82) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3367900 | 0.90 | MAOB (0.82) | MAOBMAOATP53LMNAPOLB | |
| SCHEMBL3366544 | 0.89 | MAOA (0.81) | MAOBMAOATP53LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861363-B1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-09-28 | — | — | EP | claimed |
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | claimed |
| US-7501528-B2 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | claimed |
| US-7485731-B2 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | claimed |
| EP-1861362-B1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | claimed |
| EP-1861363-A1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-05 | — | — | EP | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | claimed |
| WO-2006097270-A1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | claimed |
| US-20060211869-A1 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | US | claimed |
| US-20060211868-A1 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | US | claimed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| US-9562009-B2 | Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562009-B2 | Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2005026373-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885MAOA 2/4885TP53 4879/4885 |
| US-20060211869-A1 | Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | CYP4B1, CYP3A4, IL4 | MAOB 308/4885MAOA 2703/4885TP53 2913/4885 |
| US-20060211868-A1 | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives | CYP4B1, CYP3A4, PAH | MAOB 227/4885MAOA 2270/4885TP53 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.